Sartorius stock: Barclays raises target for Sartorius stock from EUR 300.00 to EUR 310.00

Published on 10/20/2026 at 15:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2025 revenue was EUR 3.5 billion. Sartorius stock costs EUR 262.60 on October 20, 2026, up 0.84 percent versus the Xetra close of October 19, 2026.

Analyst target and reporting date

Barclays raised its Sartorius target from EUR 300.00 to EUR 310.00 on September 30, 2026.
Fiscal 2025 revenue reached EUR 3.5 billion, up 7.60 percent year over year.
Sartorius stock costs EUR 262.60 at Lang & Schwarz on October 20, 2026 at 3:41 p.m. CEST, 0.84 percent above the Xetra close of October 19, 2026.
The next quarterly results are scheduled for October 22, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Barclays raised its Sartorius target from EUR 300.00 to EUR 310.00 on September 30, 2026 and kept its Overweight rating. The move came in an analyst note ahead of the quarterly report, according to finanzen.at. Sartorius stock was trading at EUR 262.60 at Lang & Schwarz on October 20, 2026 at 3:41 p.m. CEST, up 0.84 percent versus the Xetra close of October 19, 2026 at EUR 260.40.

Barclays sees more value

The new EUR 310.00 target leaves the share 18.04 percent below Barclays' valuation level, calculated against the Lang & Schwarz price. Barclays analyst Charles Pitman-King expected Sartorius to place its annual objectives around the middle of the existing corridor in the September 30, 2026 note.

The company reported fiscal 2025 sales revenue of EUR 3.5 billion, an increase of 7.60 percent from the prior year. Its underlying EBITDA margin was 29.70 percent for fiscal 2025, according to Sartorius.

What does the price show?

The share stood 3.42 percent below its 52-week high of EUR 271.90 on October 20, 2026. Its market capitalization was EUR 16.2 billion and its price-to-earnings ratio was 92.79 on the same date. The 52-week low was EUR 198.50, leaving the stock 32.37 percent above that level.

Valuation and reporting date

Sartorius is listed on Xetra and belongs to the MDAX. The next quarterly results are scheduled for October 22, 2026, with a conference call listed for 1:00 p.m. CEST on that date on the company's investor-relations page.

Comparison with peers

Sartorius: up 0.84 percent, P/E 92.79, market capitalization EUR 16.2 billion.

Thermo Fisher Scientific (NYSE, USD): up 0.56 percent, P/E 36.79, market capitalization USD 252.6 billion.

Danaher (NYSE, USD): up 0.33 percent, P/E 39.98, market capitalization USD 158.3 billion.

Stock level and next date

The immediate market frame is defined by the analyst target, the wide valuation gap to larger US peers and the October 22 reporting date. The current euro quotation remains below both the Barclays target and the 52-week high.

The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.